Currently Recruiting Clinical Trials

Currently Recruiting Clinical Trials are listed below. If you have any questions about our current research, please contact our research department at or call 734-714-0523.

Currently Recruiting Clinical Trials


  • In Active Ulcerative Colitis- A Randomized Controlled Trial for Determination of the Optimal Treatment Target (Treatment algorithms will feature the use of vedolizumab) (VERDICT)

  • A Phase 2, Randomized , Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate  the Efficacy, Safety, and  Pharmacokinetics  of  BFKB8488A Compared  With Placebo In  Patients  With  Nonalcoholic  Steatohepatitis (BANFF)

  • A Randomized, Placebo-controlled, Double-blind, Parallel group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis (Oral AMT-101) 

  • A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)

  • A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn's Disease (LATTICE)

  • A Phase 2/3, Randomized, Double-Blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease (GALAXI) 

  • A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in subjects with Ulcerative Colitis (AbbVie M14-533)